Friday, July 10, 2026
🇺🇸 FDA

pharma · Hypophosphatasia · Paroxysmal Nocturnal Hemoglobinuria

Alexion Europe SAS

Alexion Europe SAS trial registry — 35 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
EU HQ
89 Employees
EMA registrant Type
Company details
Status
Public
HQ
EU
Employees
89
Programs
33
Drugs
40
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Trials

Alexion Europe SAS clinical trials

Registry index of 35 ClinicalTrials.gov studies linked to Alexion Europe SAS programs — each row shows trial ID, program name, phase, status, and indication.

Alexion Europe SAS trial registry — 35 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for Alexion Europe SAS.

  1. ALXN1210-IgAN-325 — Phase 3

    Clinical update

  2. AZP-3601-CLI-002 — Phase 3

    Clinical update

  3. ALXN2220-ATTRCM-301 — Phase 3

    Clinical update

  4. ALXN1850-HPP-303 — Phase 3

    Clinical update

  5. ALXN1210-TMA-313 — Phase 3

    Clinical update

  6. ALXN1210-NEPH-202 — Phase 2

    Clinical update

  7. AA-HPP-407 — Approved

    Clinical update

  8. ALXN2420-Acro-201 — Phase 2

    Clinical update

Trial registry

35 studies

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.